Loading company
Enliven Therapeutics, Inc.
ELVN · Nasdaq · ·
Next earnings: November 11, 2026
$46.51+1.1%Sep 29 close
- 1M
- -19.6%
- 6M
- +27.1%
- 1Y
- +127.2%
- 5Y
- +178.2%
ELVN · Nasdaq · ·
Next earnings: November 11, 2026
$46.51+1.1%Sep 29 close
Enliven Therapeutics, Inc. is scheduled to report next on November 11, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Profit | -$32.5M | -$25.3M | -28.22% |
| Profit per share | -$0.49 | -$0.49 | 0.00% |
| Free Cash Flow | -$18.6M | -$17.2M | -8.34% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Enliven Therapeutics, Inc. has no earnings call transcript available.
“The second quarter was an important period for Enliven as we announced compelling updated clinical data for ELVN-001, reached alignment with the FDA on key components of the ENABLE-2 Phase 3 2L+ trial design, and significantly strengthened our balance sheet,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven's discovery process combines deep insights into clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California. To learn more, visit www.enliventherapeutics.com and connect with us on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Enliven Therapeutics, Inc.’s Item 2.02 8-K filed August 5, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.